N/A
N=10
Response Inhibition in Tourette Syndrome
Tourette Syndrome
Bottom Line
View on ClinicalTrials.gov: NCT03628703 ↗Enrolled (actual)
10
Serious AEs
0.0%
Results posted
Apr 2024
Primary outcome: Primary: Stop Signal Reaction Time (SSRT) — 249; 245 milliseconds — p=0.49
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Repetitive TMS (Device)
- Age
- Pediatric · 10+ yrs
- Sex
- All
- Sponsor
- Children's Hospital Medical Center, Cincinnati
- Primary completion
- Jun 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Stop Signal Reaction Time (SSRT) |
249; 245 | 0.49 |
Summary
Tics are the hallmark symptoms in Tourette Syndrome. Patients with Tourette Syndrome have difficulties controlling unwanted movements. The ability to control the motor system involves the pre-supplementary motor area (pre-SMA) in the brain. In this study, we will use Transcranial Magnetic Stimulation to modulate the pre-SMA and determine effect on the ability to stop an unwanted action in a behavior task (stop signal task).
Eligibility Criteria
Inclusion Criteria
- Tourette Syndrome
Exclusion Criteria
- Autism spectrum disorder
- Mood disorder
- Epilepsy
- Implanted medical device (e.g. pacemaker, shunt, pumps)
Data sourced from ClinicalTrials.gov (NCT03628703). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.